# Lanadelumab in Participants Hospitalized With COVID-19 Pneumonia

> **NCT04460105** · PHASE1 · WITHDRAWN · sponsor: **Shire**

## Conditions studied

- COVID-19 Pneumonia

## Interventions

- **DRUG:** Lanadelumab
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT04460105
- **Lead sponsor:** Shire
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2020-10-31
- **Primary completion:** 2021-01-27
- **Final completion:** 2021-01-27
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Study was withdrawn due to challenges in site recruitment and lack of patient enrollment
- **Last updated:** 2020-10-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04460105

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04460105, "Lanadelumab in Participants Hospitalized With COVID-19 Pneumonia". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT04460105. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*